|
136 |
자궁체부암 |
Lymphadenectomy or sentinel node biopsy for the management of endometrial cancer.
|
2025-09-26 |
28 |
|
135 |
자궁체부암 |
Fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer.
|
2025-09-26 |
11 |
|
134 |
자궁체부암 |
The challenge of molecular stratification in No Specific Molecular Profile endometrial cancer.
|
2025-09-26 |
7 |
|
133 |
자궁체부암 |
Maintenance olaparib after platinum-based chemotherapy for advanced/metastatic endometrial cancer: GINECO randomized phase IIb UTOLA trial.
|
2025-09-26 |
5 |
|
132 |
자궁체부암 |
Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial
|
2025-09-26 |
4 |
|
131 |
난소암 |
Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201
|
2025-09-26 |
8 |
|
130 |
난소암 |
Patient-reported outcomes in the subpopulation of patients with mismatch repair-deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy compared with chemotherapy alone in the ENGOT-EN6-NSGO/GOG3031/RUBY trial
|
2025-09-26 |
5 |
|
129 |
난소암 |
Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial
|
2025-09-26 |
5 |
|
128 |
난소암 |
Nivolumab and Ipilimumab Combination Treatment in Advanced Ovarian and Endometrial Clear Cell Cancers: A Nonrandomized Clinical Trial
|
2025-09-26 |
4 |
|
127 |
난소암 |
Primary Analysis of EPIK-O/ENGOT-ov61: Alpelisib Plus Olaparib Versus Chemotherapy in Platinum-Resistant or Platinum-Refractory High-Grade Serous Ovarian Cancer Without BRCA Mutation
|
2025-09-26 |
3 |
